Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT06205056RecruitingPhase 1
HIV vaccine safety and immune response test
This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.
KampalaAges 18–50 - NCT06205121RecruitingPhase 2
Testing a new drug for active lung sarcoidosis
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06205953Recruiting
European registry for newly diagnosed AL amyloidosis
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
HeidelbergAges 18–99 - NCT06206174RecruitingPhase 1/Phase 2
Study of TGRX-814 for blood cancers
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06207123RecruitingPhase 1/Phase 2
New drug combo for T-cell leukemia or lymphoma
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06207812Recruiting
Skin Condition in Youth: Long-Term Study
This study looks at the long-term health of people who were diagnosed with a rare skin lymphoma (mycosis fungoides) or a related skin condition (lymphomatoid papulosis) before age 20. Researchers want to learn how these conditions affect people over time.
Houston, TexasAges 18 years+ - NCT06208514Recruiting
Brief Pain Exposure Therapy for chronic pain conditions
This study tests a type of talk therapy called Brief Pain Exposure Therapy (BPET) for people with certain chronic pain conditions like fibromyalgia, lupus, or chronic low back pain. It aims to help reduce pain by changing how your brain responds to it.
Ann Arbor, MichiganAges 18 years+ - NCT06208657RecruitingPhase 1/Phase 2
Personalized cancer therapy for kids and teens
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
Newcastle, New South WalesAges birth–21 years - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06209606RecruitingEarly Phase 1
Blood test study for multiple myeloma progression
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
West Hollywood, CaliforniaAges 18 years+ - NCT06212323Recruiting
Monitoring high-risk smoldering myeloma over time
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
Salt Lake City, UtahAges 18 years+ - NCT06213311RecruitingPhase 2
CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Houston, TexasAges 18 years+ - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT06215118RecruitingPhase 1
Combination therapy for relapsed or refractory multiple myeloma
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
Coral Gables, FloridaAges 18 years+ - NCT06216535RecruitingPhase 2
Escitalopram for frequent asthma attacks
This study tests whether the antidepressant escitalopram can reduce asthma attacks in people who have frequent, severe flare-ups despite using their regular inhalers. It may help if you have moderate to severe asthma and have had 3 or more attacks needing steroids in the past year.
Dallas, TexasAges 18–75 - NCT06216600Recruiting
Women's strength and resilience program for HIV and substance use
This study tests a program for women living with HIV who also struggle with substance use or heavy drinking. It combines exercise and support to help build strength and resilience. You may qualify if you've missed some HIV medications, have a detectable viral load, and have experienced violence.
San Diego, CaliforniaAges 18 years+ - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Stanford, CaliforniaAges 18–75 - NCT06218927Recruiting
Stem cell transplant and bladder function in MS
This study looks at whether a stem cell transplant (AHSCT) can improve bladder problems and quality of life in people with multiple sclerosis (MS). It compares people getting this treatment with those on standard MS therapy.
Ostrava, Moravian-Silesian RegionAges 18 years+ - NCT06219304Recruiting
High intensity training for multiple sclerosis
This trial tests whether high intensity exercise can improve both movement and thinking in people with multiple sclerosis. It might help if you can walk but need some support for balance.
Milan, MIAges 18 years+ - NCT06219356RecruitingPhase 1
Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06220032RecruitingPhase 3
Preventing heart damage from chemotherapy in lymphoma
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
's-HertogenboschAges 18 years+ - NCT06220487RecruitingPhase 2
New drug combo for Ph+ ALL without transplant
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06221631Recruiting
Brain aging in MS and healthy people
This study compares how the brain ages in people with multiple sclerosis (MS) and healthy volunteers. It uses MRI scans and other tests to understand brain aging better.
Bern, Canton of BernAges 18–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.